FSPKF:OTO-Fisher & Paykel Healthcare Corp. Ltd. (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC Pink

Last Closing

USD 18.06

Change

0.00 (0.00)%

Market Cap

USD 3.82B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Fisher & Paykel Healthcare Corp Ltd is a designer, manufacturer and marketer of medical device products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-15 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOF EssilorLuxottica Société ano..

N/A

USD 102.50B
ESLOY Essilor International SA

N/A

USD 101.63B
HOCPF HOYA Corporation

N/A

USD 40.96B
HOCPY Hoya Corp

N/A

USD 40.66B
RSMDF Resmed Inc DRC

N/A

USD 31.10B
CLPBF Coloplast A/S

N/A

USD 27.05B
CLPBY Coloplast A

N/A

USD 26.98B
TRUMF Terumo Corporation

N/A

USD 26.03B
TRUMY Terumo Corp ADR

N/A

USD 24.81B
SAUHF Straumann Holding AG

N/A

USD 21.26B

ETFs Containing FSPKF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 27.99% 90% A- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.99% 87% B+ 79% B-
Trailing 12 Months  
Capital Gain 28.82% 90% A- 80% B-
Dividend Return 2.82% 90% A- 40% F
Total Return 31.63% 87% B+ 80% B-
Trailing 5 Years  
Capital Gain 79.43% 92% A 85% B
Dividend Return 16.30% 82% B 54% F
Total Return 95.74% 96% N/A 85% B
Average Annual (5 Year Horizon)  
Capital Gain 9.79% 54% F 55% F
Dividend Return 11.99% 54% F 54% F
Total Return 2.20% 71% C- 41% F
Risk Return Profile  
Volatility (Standard Deviation) 45.66% 51% F 53% F
Risk Adjusted Return 26.26% 64% D 61% D-
Market Capitalization 3.82B 75% C 90% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector